REGENEUS LTD (RGS)

Overview

Regeneus Ltd, a regenerative medicine company, develops and commercializes stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions in Australia. The company provides HiQCell, an autologous adipose derived stem cell therapy for human osteoarthritis and other musculoskeletal conditions. It also offers animal health products comprising CryoShot, an allogeneic cell-based product for use as an intra-articular injection for osteoarthritis, an adjunct to joint surgery, and an intra-lesional injection for tendinopathy in canine and equine markets; and Kvax, an autologous therapeutic cancer vaccine. In addition, the company is developing a stem cell secretions cream for inflammatory skins conditions, such as acne, rosacea, and psoriasis; and Progenza, an allogeneic cell therapy treatment for human osteoarthritis. Regeneus Ltd was founded in 2007 and is headquartered in Pymble, Australia.

InvestSMART Publishing Pty Ltd holds Australian Financial Securities Licence (AFSL) 282288.
The content of this website is general in nature and does not take the personal situation of any user of this website into consideration.
A user of this website should seek financial advice specific to that user’s situation before making any financial decision.
Past performance of any security or financial product is not a reliable indicator of future performance. InvestSMART Publishing Pty Ltd
encourages users of this website to view investing as a long-term pursuit.